AVEO Pharmaceuticals (AVEO Pharmaceuticals) Gross Margin % : 86.98% (As of Sep. 2022)

View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. AVEO Pharmaceuticals's Gross Profit for the three months ended in Sep. 2022 was $26.49 Mil. AVEO Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was $30.45 Mil. Therefore, AVEO Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2022 was 86.98%.

The historical rank and industry rank for AVEO Pharmaceuticals's Gross Margin % or its related term are showing as below:

AVEO' s Gross Margin % Range Over the Past 10 Years
Min: 87.81 Med: 88.8 Max: 88.8
Current: 87.81

During the past 13 years, the highest Gross Margin % of AVEO Pharmaceuticals was 88.80%. The lowest was 87.81%. And the median was 88.80%.

AVEO's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.905 vs AVEO: 87.81

AVEO Pharmaceuticals had a gross margin of 86.98% for the quarter that ended in Sep. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for AVEO Pharmaceuticals was 0.00% per year.

AVEO Pharmaceuticals Gross Margin % Historical Data

The historical data trend for AVEO Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Gross Margin % Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Gross Margin %

Get a 7-Day Free Trial

88.80

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Gross Margin %	Get a 7-Day Free Trial															88.51	88.48	88.37	87.89	86.98

Competitive Comparison of AVEO Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, AVEO Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVEO Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Gross Margin % falls into.

AVEO Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

AVEO Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )	=	Gross Profit (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	37.6	/	42.295
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(42.295 - 4.737)	/	42.295
	=	88.80 %

AVEO Pharmaceuticals's Gross Margin for the quarter that ended in Sep. 2022 is calculated as

Gross Margin % (Q: Sep. 2022 )	=	Gross Profit (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	26.5	/	30.449
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(30.449 - 3.964)	/	30.449
	=	86.98 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

AVEO Pharmaceuticals (NAS:AVEO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AVEO Pharmaceuticals had a gross margin of 86.98% for the quarter that ended in Sep. 2022 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

AVEO Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Executives

Jebediah Ledell	officer: Chief Operating Officer	C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey	director, officer: President & CEO	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso	officer: Chief Commercial Officer	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell	10 percent owner
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera	officer: Chief Financial Officer	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring	director	AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202